stockrow
Saturday 7 November 2026
Export SGMT’s income statement to Excel — free account
Sagimet Biosciences Inc.
SGMT Healthcare Biotechnology
Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million.
- EPS
- +18.8%
- Free cash flow
- −22.0%
Quarter to June 2026, against a year earlier
9.82
0.70
+7.68%
Follow SGMT
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(39.78%) | (38.20%) | (36.04%) | (24.37%) | |
| (38.04%) | (36.89%) | (34.27%) | (23.49%) | ||
ROIC |
(1,569.06%) | 0.00% | 0.00% | (205.24%) | |
Return on Tangible Assets |
(52.27%) | (45.86%) | (42.48%) | (19.73%) | |
Free Cash Flow per Share |
(1.38) | (1.41) | (1.22) | (0.79) | |
Free Cash Flow |
(44.84) | (45.65) | (39.72) | (41.72) | |
| Other line items | |||||
Cash ROIC |
(19.00%) | (20.33%) | (19.19%) | (8.41%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.89 | 0.91 | 0.89 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.38) | (1.41) | (1.22) | (0.79) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026